Ferric carboxymaltose is approved for IV administration only.Monitor patients during, and for 30 minutes after, administration of ferric carboxymaltose. Life-threatening hypersensitivity reactions are a known risk with all IV iron preparations. Ensure cardiopulmonary resuscitation equipment is available.Prospective trials have demonstrated efficacy in patients with inflammatory bowel disease, chronic kidney disease, menorrhagia and postpartum anaemia. Ferric carboxymaltose can improve Hb levels and iron stores for iron-deficiency anaemia associated with a variety of conditions.

There are no head-to-head comparisons with IV iron polymaltose.

Efficacy relative to IV iron polymaltose is assumed but not established.

Levels and replenished iron stores as effectively as IV iron sucrose but requiring fewer doses. In key trials, ferric carboxymaltose increased

Comparable efficacy to that of IV iron sucrose.

A maximum dose of 1000 mg iron can be delivered intravenously over 15 minutes, which may make it a suitable treatment for iron-deficiency anaemia outside of the hospital setting.

Hearts of iron 4 not responding